REGN - שווי החברה ברכישה מלאה Regeneron Pharmaceuticals

This price chart on GURU.Markets for Regeneron Pharmaceuticals (REGN) shows an Enterprise Value of 90232.71. Regeneron Pharmaceuticals (REGN) generates revenue from exclusive treatments for orphan diseases, leveraging patent protection to maintain significant pricing power. Growth is based on protecting core products and actively seeking new antibodies in immunology. Meanwhile, substantial cash reserves and profits from ophthalmology drugs mitigate the risks of losing exclusive rights.

This indicator reflects the total enterprise value, combining market capitalization with net debt to determine the actual cost of a full asset buyout. The price action of the enterprise value confirms the resilience of Regeneron Pharmaceuticals (REGN), as a diversified portfolio of oncology and cardiology drugs, supplemented by a broad pipeline, minimizes patent risks and justifies the company's current valuation from a strategic investor's perspective.